This article is more than 5 years old. Information may no longer be current.

pSivida reports 100% royalty revenue increase for Retisert

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — Royalty revenue paid to pSivida Ltd. for the Retisert drug delivery device totaled $248,000 in the third quarter of 2006, roughly a 100% increase over the previous quarter, according to the company. However, because of a royalty agreement with Bausch & Lomb, the actual revenues pSivida earned in the quarter are double that amount, according to a press release from the company.

PSivida also announced that its Medidur drug delivery device for diabetic macula edema entered phase 3 trials, and its eye drop formulation of mifipristone has entered into a phase 2b clinical trial.